Inventor
Richard B. Dorshow
Inventor
St. Louis, MO, US
Overview
Patents· 84 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes34%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
C07DHeterocyclic compounds20%
C09BOrganic dyes or closely-related compounds for producing dyes, e.g. pigments10%
A61BDiagnosis3%
C07KPeptides2%
A61LMethods or apparatus for sterilising materials or objects in general2%
B01JChemical or physical processes, e.g. catalysis or colloid chemistry1%
B82YSpecific uses or applications of nanostructures1%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
PatentTitleYear
11,077,211Compositions and methods for assessing gut function202110,967,096Tissue sealant compositions, vascular closure devices, and uses thereof202110,960,104Tissue sealant compositions, vascular closure devices, and uses thereof202110,898,591Compositions and methods for assessing eye vasculature202110,881,759Tissue sealant compositions, vascular closure devices, and uses thereof202110,695,445Methods of using optical agents202010,617,687Fluorescent pyrazine derivatives and methods of using the same in assessing renal function202010,525,149Compositions and methods for assessing eye vasculature202010,370,362Pyrazine derivatives with extended conjugation and methods of using the same in optical applications2019RE047413Pyrazine derivatives and uses thereof in renal monitoring2019RE047255Pyrazine derivatives and uses thereof in renal monitoring201910,137,207Methods of using optical agents20189,662,387'Functional, cross-linked nanostructures for tandem optical imaging and therapy'20179,527,858'Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers'20169,518,062'Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers'20169,480,687'Pyrazine derivatives and uses thereof in renal monitoring'20169,433,700'Tissue sealant compositions, vascular closure devices, and uses thereof'20169,376,399'Fluorescent pyrazine derivatives and methods of using the same in assessing renal function'20169,295,650'Functional, cross-linked nanostructures for tandem optical imaging and therapy'20169,283,288'Methods of using optical agents'20169,216,963'Pyrazine derivatives with extended conjugation and methods of using the same in optical applications'20159,114,160'Pyrazine derivatives and uses thereof in renal monitoring'20158,829,020'Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers'20148,778,309'Fluorescent pyrazine derivatives and methods of using the same in assessing renal function'20148,722,685'Pyrazine derivatives and uses thereof in renal monitoring'20148,697,871'Integrated photoactive agents and uses thereof'20148,664,392'Pyrazine derivatives for bioconjugation'20148,658,433'Dye compounds as photoactive agents'20148,481,734'Pyrazine derivatives and uses thereof, including in medical imaging and visualization applications'20138,350,032'Integrated photoactive agents for real-time monitoring of hemostasis'20138,313,729'Integrated photoactive small molecules and uses thereof'20128,115,000'Pyrazine derivatives and uses thereof in renal monitoring'20127,888,378'Thiadiazole compounds and uses thereof'20117,790,144'Receptor-avid exogenous optical contrast and therapeutic agents'20107,767,194'Optical diagnostic and therapeutic agents and compositions'20107,674,902'Luminescent metal complexes for monitoring renal function'20107,608,244'Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients'20097,566,444'Versatile hydrophilic dyes'20097,556,797'Minimally invasive physiological function monitoring agents'20097,514,069'Tumor-targeted optical contrast agents'20097,510,700'Pathological tissue detection and treatment employing targeted benzoindole optical agents'20097,504,087'Receptor-avid exogenous optical contrast and therapeutic agents'20097,468,177'Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients'20087,438,894'Dyes for organ function monitoring'20087,431,925'Internal image antibodies for optical imaging and therapy'20087,427,657'Aromatic sulfenates for type 1 phototherapy'20087,351,807'Cyanine-sulfenates for dual phototherapy'20087,303,926'Methods and compositions for dual phototherapy'20077,297,325'Hydrophilic light absorbing compositions for determination of physiological function'20077,252,815'Pathological tissue detection and treatment employing targeted benzoindole optical agents'20077,235,685'Aromatic sulfenates for type I phototherapy'20077,230,088'Compounds for dual photodiagnosis and therapy'20077,201,892'Pathological tissue detection and treatment employing targeted optical agents'20077,198,778'Tumor-targeted optical contrast agents'20077,175,831'Light sensitive compounds for instant determination of organ function'20077,128,896'Pathological tissue detection and treatment employing targeted benzoindole optical agents'20067,011,817'Hydrophilic cyanine dyes'20066,939,532'Versatile hydrophilic dyes'20056,887,854'Compounds as dynamic organ function monitoring agents'20056,761,878'Pathological tissue detection and treatment employing targeted benzoindole optical agents'20046,747,151'Azo compounds for type I phototherapy'20046,733,744'Indole compounds as minimally invasive physiological function monitoring agents'20046,716,413'Indole compounds as tissue-specific exogenous optical agents'20046,706,254'Receptor-avid exogenous optical contrast and therapeutic agents'20046,673,334'Light sensitive compounds for instant determination of organ function'20046,669,926'Hydrophilic light absorbing indole compounds for determination of physiological function in critically ill patients'20036,663,847'Dynamic organ function monitoring agents'20036,656,451'Indole compounds as novel dyes for organ function monitoring'20036,641,798'Tumor-targeted optical contrast agents'20036,485,704'Azo compound for type I pototherapy'20026,423,547'Non-covalent bioconjugates useful for diagnosis and therapy'20026,395,257'Dendrimer precursor dyes for imaging'20026,280,703'Simultaneous multimodal measurement of physiological function'20016,277,841'Quinoline ligands and metal complexes for diagnosis and therapy'20016,264,920'Tunable indocyanine dyes for biomedical applications'20016,264,919'Indocyanine dyes'20016,228,344'Method of measuring physiological function'20016,217,848'Cyanine and indocyanine dye bioconjugates for biomedical applications'20016,190,641'Indocyanine dyes'20016,183,726'Versatile hydrophilic dyes'20016,180,086'Hydrophilic cyanine dyes'20016,180,085'Dyes'20016,180,087'Tunable indocyanine dyes for biomedical applications'20015,928,625'Method of measuring physiological function'1999Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1999–2011Patents assigned to MALLINCKRODT INC (50)· patent assignee history
1999–2021Based in St. Louis, MO, US· patent location history
2012–2016Patents assigned to DORSHOW RICHARD B (13)· patent assignee history
2012–2016Patents assigned to RAJAGOPALAN RAGHAVAN (11)· patent assignee history
2012–2016Patents assigned to NEUMANN WILLIAM L (9)· patent assignee history
2014–2021Based in St. Charles, MO, US· patent location history
2015–2021Patents assigned to MEDIBEACON INC (16)· patent assignee history
2016Based in Hazelwood, MO, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MALLINCKRODT INC | 50 | 1999–2011 |
| MEDIBEACON INC | 16 | 2015–2021 |
| DORSHOW RICHARD Bself | 13 | 2012–2016 |
| RAJAGOPALAN RAGHAVAN | 11 | 2012–2016 |
| NEUMANN WILLIAM L | 9 | 2012–2016 |
Locations
| Location | Patents | Span |
|---|---|---|
| St. Louis, MO, US | 75 | 1999–2021 |
| St. Charles, MO, US | 7 | 2014–2021 |
| Hazelwood, MO, US | 2 | 2016 |